# AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)

> **NCT00240331** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2776 (actual)

## Conditions studied

- Renal Failure

## Interventions

- **DRUG:** 10mg Rosuvastatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00240331
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 2776 (ACTUAL)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00240331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00240331, "AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00240331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*